HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration

• Autores principales: Ying Lu (Autor), Fan Shen (Autor), Wen-Qiang He (Autor), An-Qi Li (Autor), Ming-Hua Li (Autor), Xiao-Li Feng (Autor), Yong-Tang Zheng (Autor), Wei Pang (Autor)
• Formato: Libro
• Publicado: Elsevier, 2023-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

The continuously emerging SARS-CoV-2 variants pose a great challenge to the efficacy of current drugs, this necessitates the development of broad-spectrum antiviral drugs. In the previous study, we designed a recombinant protein, heptad repeat (HR) 121, as a variant-proof vaccine. Here, we found it...